{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:54:19Z","timestamp":1768416859300,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013773","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000}}],"reference-count":146,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013773.pub2","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T10:26:19Z","timestamp":1717755979000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cytoreductive nephrectomy in metastatic renal cell carcinoma"],"prefix":"10.1002","volume":"2024","author":[{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA"},{"name":"Department of Urology; University of Minnesota; Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onuralp","family":"Ergun","sequence":"additional","affiliation":[{"name":"Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA"},{"name":"Department of Urology; University of Minnesota; Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie","family":"Uhlig","sequence":"additional","affiliation":[{"name":"Department of Urology; University Medical Center; Goettingen Germany"},{"name":"UroEvidence@Deutsche Gesellschaft f\u00fcr Urologie; Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bellut","sequence":"additional","affiliation":[{"name":"UroEvidence@Deutsche Gesellschaft f\u00fcr Urologie; Berlin Germany"},{"name":"Department of Urology and Pediatric Urology; University Hospital Erlangen; Erlangen Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN); Erlangen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C","family":"Risk","sequence":"additional","affiliation":[{"name":"Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A","family":"Lyon","sequence":"additional","affiliation":[{"name":"Library Services; Children's Mercy Hospital; Kansas City Missouri USA"},{"name":"Center for Evidence-Based Policy; Portland Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Kunath","sequence":"additional","affiliation":[{"name":"UroEvidence@Deutsche Gesellschaft f\u00fcr Urologie; Berlin Germany"},{"name":"Medizinische Fakult\u00e4t am Medizincampus Oberfranken; Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg; Erlangen Germany"},{"name":"Department of Urology and Pediatric Urology; Klinikum Bayreuth GmbH; Bayreuth Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.eururo.2021.06.009","article-title":"Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy?","volume":"80","author":"Mejean","year":"2021","journal-title":"European Urology"},{"issue":"18_suppl","key":"10.1002\/14651858.CD013773.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3","article-title":"CARMENA: cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma-results of a phase III noninferiority trial","volume":"36","author":"M\u00e9jan","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013773.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"9286","key":"10.1002\/14651858.CD013773.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/s0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bju.15625","article-title":"Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer (SURTIME) trial","volume":"130","author":"Abu-Ghanem","year":"2022","journal-title":"BJU International"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/S1569-9056(18)30856-X","article-title":"Surgical safety of immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. Data from the EORTC randomized trial 30073 SURTIME","volume":"17","author":"Bex","year":"2018","journal-title":"European Urology Supplements"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"v622","DOI":"10.1093\/annonc\/mdx440.030","article-title":"Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)","volume":"28","author":"Bex","year":"2017","journal-title":"Annals on Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.eururo.2019.06.006","article-title":"Surgical safety of cytoreductive nephrectomy following sunitinib: results from the multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME)","volume":"76","author":"De Bruijn","year":"2019","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0011|cit11","unstructured":"Immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer clinicaltrials.gov\/show\/NCT01099423"},{"issue":"23","key":"10.1002\/14651858.CD013773.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013773.pub2-BIB0013|cit13","first-page":"2405","article-title":"Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era","volume":"34","author":"Abern","year":"2014","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"627025","DOI":"10.3389\/fonc.2020.627025","article-title":"Dissecting outcomes: should cytoreductive nephrectomy be performed for patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation?","volume":"10","author":"Adashek","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013773.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/jamaoncol.2016.1198","article-title":"Up-front targeted therapy prior to cytoreductive nephrectomy in treatment-naive patients with metastatic renal cell carcinoma","volume":"2","author":"Agarwal","year":"2016","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"v359-60","DOI":"10.1093\/annonc\/mdz249.007","article-title":"Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab 1 axitinib (A 1 Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)","volume":"30","author":"Albiges","year":"2019","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013773.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"e253952022","DOI":"10.7759\/cureus.25395","article-title":"The role of cytoreductive nephrectomy and targeted therapy on outcomes of patients with metastatic sarcomatoid renal cell carcinoma: a population-based analysis","volume":"14","author":"Al-Juhaishi","year":"2022","journal-title":"Cureus"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"166.e1","DOI":"10.1016\/j.urolonc.2022.01.005","article-title":"Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma","volume":"40","author":"Andrews","year":"2022","journal-title":"Urologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0019|cit19","first-page":"e1178-9","article-title":"Testing the external validity of CARMENA trial comparing sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"18","author":"Arora","year":"2019","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1097\/01.JU.0000555043.11071.bb","article-title":"Testing the external validity of CARMENA trial comparing sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"201","author":"Arora","year":"2019","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.2020.38.6_suppl.608","article-title":"Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): a propensity score-based analysis","volume":"38 Suppl 6","author":"Bakouny","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.eururo.2022.10.004","article-title":"Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium","volume":"83","author":"Bakouny","year":"2023","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD013773.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.clgc.2014.03.012","article-title":"Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study","volume":"12","author":"Bamias","year":"2014","journal-title":"Clinical Genitourinary Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/kca-210010","article-title":"\"PROBE\"ing the pole of cytoreductive nephrectomy in advanced renal cancer","volume":"6","author":"Bell","year":"2022","journal-title":"Kidney Cancer Journal"},{"issue":"6","key":"10.1002\/14651858.CD013773.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/s0302-2838(02)00404-9","article-title":"The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ","volume":"42","author":"Bex","year":"2002","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.eururo.2005.09.011","article-title":"Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study","volume":"49","author":"Bex","year":"2006","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.urology.2011.05.034","article-title":"A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ","volume":"78","author":"Bex","year":"2011","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD013773.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.juro.2018.03.077","article-title":"Comparative survival following initial cytoreductive nephrectomy versus initial targeted therapy for metastatic renal cell carcinoma","volume":"200","author":"Bhindi","year":"2018","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.eururo.2020.04.038","article-title":"Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma","volume":"78","author":"Bhindi","year":"2020","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.urolonc.2008.11.016","article-title":"Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma: Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG, Department of Urology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX","volume":"27","author":"Blute","year":"2009","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.17650\/1726-9776-2019-15-4-65-72","article-title":"Efficacy of incomplete metastasectomy in combination with targeted therapy in metastatic kidney cancer patients","volume":"15","author":"Borisov","year":"2019","journal-title":"Onkourologiya"},{"issue":"6","key":"10.1002\/14651858.CD013773.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/iju.12004","article-title":"Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: implications for multimodal therapy","volume":"20","author":"Capitanio","year":"2013","journal-title":"International Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"15272","DOI":"10.1038\/s41598-019-51548-4","article-title":"Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy","volume":"9","author":"Carvalho","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0034|cit34","first-page":"S43","article-title":"Impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy-a performance status based prospective study","volume":"33 Suppl 1","author":"Chatterjee","year":"2017","journal-title":"Indian Journal of Urology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/CIA.S243902","article-title":"The effect of cytoreductive partial nephrectomy in elderly patients with metastatic renal cell carcinoma","volume":"15","author":"Chen","year":"2020","journal-title":"Clinical Interventions in Aging"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.asjsur.2022.04.008","article-title":"Shifting role of cytoreductive nephrectomy according to type of systemic therapy: a nationwide cohort study","volume":"46","author":"Choi","year":"2023","journal-title":"Asian Journal of Surgery"},{"issue":"9","key":"10.1002\/14651858.CD013773.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1002\/ijc.28553","article-title":"Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era","volume":"134","author":"Conti","year":"2014","journal-title":"International Journal of Cancer"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013773.pub2-BIB0038|cit38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS761","article-title":"Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab\/nivolumab for metastatic kidney cancer (CYTOSHRINK)","volume":"38","author":"Lalani","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.euo.2019.12.004","article-title":"Deferred cytoreductive nephrectomy following presurgical vascular endothelial growth factor receptor-targeted therapy in patients with primary metastatic clear cell renal cell carcinoma: a pooled analysis of prospective trial data","volume":"3","author":"Bruijn","year":"2020","journal-title":"European Urology Oncology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0040|cit40","unstructured":"Sunitinib either before or after cytoreductive nephrectomy. A phase II trial in patients with metastatic renal cell carcinoma clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number%3A2007-005977-67"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0041|cit41","unstructured":"Fallah J Gittleman H Weinstock C Chang E Agrawal S Tang S Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US FDA pooled analysis JNCI: Journal of the National Cancer Institute 10.1093\/jnci\/djae066"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"v404","DOI":"10.1093\/annonc\/mdx376.003","article-title":"Interim analysis of the phase 3 ADAPT trial evaluating Rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC)","volume":"28 Suppl 5","author":"Figlin","year":"2017","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013773.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-19-2427","article-title":"Results of the ADAPT phase 3 study of rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma","volume":"26","author":"Figlin","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1200\/jco.2014.32.4_suppl.449","article-title":"ADAPT: An ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in advanced renal cell carcinoma (RCC)","volume":"32 Suppl 4","author":"Figlin","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0045|cit45","first-page":"230","article-title":"Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience","volume":"14 Suppl 4","author":"Franklin","year":"1996","journal-title":"Seminars in Urologic Oncology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD013773.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1200\/JCO.2019.37.15_suppl.450","article-title":"A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx)","volume":"37 Suppl 15","author":"Gao","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1200\/JCO.2018.36.15_suppl.4520","article-title":"A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx)","volume":"36 Suppl 15","author":"Gao","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1200\/JCO.2021.39.15_suppl.4582","article-title":"Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)","volume":"39 Suppl 15","author":"Ghatalia","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/ju.0000000000002495","article-title":"The role of cytoreductive nephrectomy in metastatic renal cell carcinoma: a real-world multi-institutional analysis","volume":"208","author":"Ghatalia","year":"2022","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1016\/j.annonc.2021.08.061","article-title":"665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab+ axitinib (A+ Ax) or sunitinib (S): Results from JAVELIN Renal 101","volume":"32","author":"Grimm","year":"2021","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"229","DOI":"10.17305\/bjbms.2020.4896","article-title":"The role of cytoreductive nephrectomy in renal cell carcinoma patients with liver metastasis","volume":"21","author":"Guo","year":"2021","journal-title":"Bosnian Journal of Basic Medical Sciences"},{"issue":"5","key":"10.1002\/14651858.CD013773.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.urology.2014.02.005","article-title":"High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience","volume":"83","author":"Hanzly","year":"2014","journal-title":"Urology"},{"issue":"9","key":"10.1002\/14651858.CD013773.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/iju.15193","article-title":"Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma","volume":"30","author":"Hara","year":"2023","journal-title":"International Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD013773.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.urolonc.2011.01.005","article-title":"Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)","volume":"31","author":"Harshman","year":"2013","journal-title":"Urologic Oncology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0055|cit55","first-page":"viii291","article-title":"Predict global non-interventional study: baseline characteristics of RCC patients treated with sorafenib","volume":"21","author":"J\u00e4ger","year":"2010","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013773.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"739.e9","DOI":"10.1016\/j.urolonc.2020.04.033","article-title":"The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort","volume":"38","author":"Janisch","year":"2020","journal-title":"Urologic Oncology"},{"issue":"25","key":"10.1002\/14651858.CD013773.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1200\/JCO.2008.21.3660","article-title":"Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma","volume":"27","author":"Jonasch","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.urolonc.2020.04.033","article-title":"Pazopanib for the treatment of non-clear cell renal cell carcinoma: A single-arm, open-label, multicenter, phase II study","volume":"50","author":"Jung","year":"2018","journal-title":"Cancer Research and Treatment"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"292","DOI":"10.5489\/cuaj.1122","article-title":"Impact of tyrosine kinase inhibitors and cytoreductive nephrectomy in patients with metastatic renal cell carcinoma","volume":"3","author":"Kassouf","year":"2009","journal-title":"Canadian Urological Association Journal"},{"issue":"3","key":"10.1002\/14651858.CD013773.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10147-021-02091-8","article-title":"Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era \u2013 a multi-institutional retrospective study","volume":"27","author":"Kato","year":"2022","journal-title":"International Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013773.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1002\/cam4.2222","article-title":"Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: a multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry","volume":"8","author":"Kim","year":"2019","journal-title":"Cancer Medicine"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013773.pub2-BIB0062|cit62","first-page":"TPS761","article-title":"Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab\/nivolumab for metastatic kidney cancer (CYTOSHRINK)","volume":"38","author":"Swaminath","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12957-021-02308-0","article-title":"Nephrectomy improves the survival of metastatic renal cell cancer patients with moderate to good performance status-results from a Finnish nation-wide population-based study from 2005 to 2010","volume":"19","author":"Laru","year":"2021","journal-title":"World Journal of Surgical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"78.e21","DOI":"10.1016\/j.urolonc.2017.09.030","article-title":"Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma","volume":"36","author":"Lenis","year":"2018","journal-title":"Urologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S0022-5347(01)63542-0","article-title":"Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma","volume":"159","author":"Levy","year":"1998","journal-title":"Journal of Urology"},{"issue":"12","key":"10.1002\/14651858.CD013773.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1007\/s00345-020-03107-0","article-title":"Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach","volume":"38","author":"Liu","year":"2020","journal-title":"World Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD013773.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/21681805.2020.1815833","article-title":"Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting","volume":"54","author":"Ljungberg","year":"2020","journal-title":"Scandinavian Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD013773.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.euf.2020.04.009","article-title":"Association between systemic therapy and\/or cytoreductive nephrectomy and survival in contemporary metastatic non-clear cell renal cell carcinoma patients","volume":"7","author":"Luzzago","year":"2021","journal-title":"European Urology Focus"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.urology.2017.11.014","article-title":"Comparative effectiveness of initial surgery vs initial systemic therapy for metastatic kidney cancer in the targeted therapy era: analysis of a population-based cohort","volume":"113","author":"Macleod","year":"2018","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD013773.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1590\/S1677-5538.IBJU.2015.0118","article-title":"Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA","volume":"43","author":"Manley","year":"2017","journal-title":"International Brazilian Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.juro.2008.03.047","article-title":"Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma","volume":"180","author":"Margulis","year":"2008","journal-title":"Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD013773.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.clgc.2014.06.006","article-title":"The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b","volume":"12","author":"Mutlu","year":"2014","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0073|cit73","unstructured":"Pre-surgical sutent in renal cell carcinoma (RCC) clinicaltrials.gov\/study\/NCT00715442"},{"issue":"3","key":"10.1002\/14651858.CD013773.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.urology.2011.03.009","article-title":"Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible?","volume":"78","author":"O'Malley","year":"2011","journal-title":"Urology"},{"issue":"12","key":"10.1002\/14651858.CD013773.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"836.e11","DOI":"10.1016\/j.urolonc.2021.08.015","article-title":"External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: a multicenter retrospective study","volume":"39","author":"Okita","year":"2021","journal-title":"Urologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0076|cit76","first-page":"8227-33","article-title":"Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? A comparison of primary and adjuvant approaches","volume":"23","author":"Patel","year":"2016","journal-title":"Canadian Journal of Urology"},{"issue":"10","key":"10.1002\/14651858.CD013773.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cam4.1137","article-title":"Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival","volume":"6","author":"Patel","year":"2017","journal-title":"Cancer Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1464-410X.2007.07108.x","article-title":"Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed","volume":"100","author":"Pierorazio","year":"2007","journal-title":"BJU International"},{"issue":"10","key":"10.1002\/14651858.CD013773.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.3390\/cancers12102911","article-title":"Cytoreductive nephrectomy and overall survival of patients with metastatic renal cell carcinoma treated with targeted therapy-data from the national renis registry","volume":"12","author":"Poprach","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1002\/14651858.CD013773.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.eururo.2011.05.028","article-title":"The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer","volume":"60","author":"Powles","year":"2011","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD013773.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/annonc\/mdq564","article-title":"The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer","volume":"22","author":"Powles","year":"2011","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013773.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/annonc\/mdt130","article-title":"A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer","volume":"24","author":"Powles","year":"2013","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013773.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/s0022-5347(17)39537-x","article-title":"Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells","volume":"144","author":"Robertson","year":"1990","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000338057","article-title":"Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective","volume":"89","author":"Shaw","year":"2012","journal-title":"Urologia Internationalis"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.urology.2012.10.054","article-title":"Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study","volume":"81","author":"Stroup","year":"2013","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD013773.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/0090-4295(93)90612-e","article-title":"Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma","volume":"42","author":"Walther","year":"1993","journal-title":"Urology"},{"issue":"5","key":"10.1002\/14651858.CD013773.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/s0022-5347(01)64091-6","article-title":"Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma","volume":"158","author":"Walther","year":"1997","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.2019.37.7_suppl.570","article-title":"Is cytoreductive nephrectomy necessary in metastatic renal cell carcinoma with primary kidney tumor in situ treated by sunitinib: real-world data from a single Chinese center","volume":"37 Suppl 7","author":"Ye","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013773.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/jjco\/hyac099","article-title":"Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab","volume":"52","author":"Yoshino","year":"2022","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.juro.2010.09.018","article-title":"The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy","volume":"185","author":"You","year":"2011","journal-title":"Journal of Urology"},{"issue":"15-suppl","key":"10.1002\/14651858.CD013773.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"TPS4601","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS46","article-title":"TARIBO trial: cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents","volume":"35","author":"Grassi","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013773.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"401","DOI":"10.5301\/tj.5000699","article-title":"TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery","volume":"104","author":"Verzoni","year":"2018","journal-title":"Tumori"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0093|cit93","unstructured":"Sunitinib before or after surgery in treating patients with metastatic kidney cancer clinicaltrials.gov\/ct2\/show\/NCT00626509"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0094|cit94","unstructured":"Lisager L Ahrenfeldt J Donskov F Ljungberg B Bex A Lund L Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial BMC Cancer 10.1186\/s12885-024-11987-3"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0095|cit95","unstructured":"Deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: the NORDIC-SUN-Trial clinicaltrials.gov\/ct2\/show\/NCT03977571"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0096|cit96","unstructured":"Comparing the outcome of immunotherapy-based drug combination therapy with or without surgery to remove the kidney in metastatic kidney cancer, the PROBE trial clinicaltrials.gov\/ct2\/show\/NCT04510597"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3233\/KCA-210000","article-title":"Clinical trials corner: a new look at cytoreductive nephrectomy","volume":"5","author":"Parikh","year":"2021","journal-title":"Kidney Cancer"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0098|cit98","unstructured":"The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immuno-oncology era: SEVURO-CN trial (SEVURO-CN) clinicaltrials.gov\/show\/NCT05753839"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.eururo.2022.10.004","article-title":"Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: An observational study from the international metastatic renal cell carcinoma database consortium","volume":"83","author":"Bakouny","year":"2023","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD013773.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.eururo.2020.12.005","article-title":"Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-na\u00efve metastatic clear-cell renal cell carcinoma","volume":"79","author":"Bedke","year":"2021","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2018.09.016","article-title":"Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma","volume":"75","author":"Bhindi","year":"2019","journal-title":"European Urology"},{"issue":"12","key":"10.1002\/14651858.CD013773.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1007\/s00345-021-03734-1","article-title":"Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic","volume":"39","author":"Chan","year":"2021","journal-title":"World Journal of Urology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0103|cit103","unstructured":"Covidence systematic review software Veritas Health Innovation"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0007-4551(18)30377-1","article-title":"Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?","volume":"105 Suppl 3","author":"Dariane","year":"2018","journal-title":"Bulletin du Cancer"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0105|cit105","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"360","DOI":"10.5114\/aoms.2016.59262","article-title":"Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma","volume":"12","author":"Domaga\u0142a-Haduch","year":"2016","journal-title":"Archives of Medical Science"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0108|cit108","unstructured":"EndNote Thomson Reuters"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3390\/cancers13040695","article-title":"Long-term survival outcomes of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a systematic review and individual patient data meta-analysis","volume":"13","author":"Esagian","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4111\/icu.2018.59.1.2","article-title":"Role of cytoreductive nephrectomy in the targeted therapy era: a systematic review and meta-analysis","volume":"59","author":"Garcia-Perdomo","year":"2018","journal-title":"Investigative and Clinical Urology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0111|cit111","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"7651","key":"10.1002\/14651858.CD013773.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"GRADE: what is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD013773.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10552-021-01435-z","article-title":"Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach","volume":"32","author":"Hall","year":"2021","journal-title":"Cancer Causes Control"},{"issue":"27","key":"10.1002\/14651858.CD013773.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1200\/JCO.2016.66.7931","article-title":"Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study","volume":"34","author":"Hanna","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013773.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013773.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD013773.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0119|cit119","unstructured":"Higgins JP Altman DG Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0120|cit120","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604"},{"issue":"5","key":"10.1002\/14651858.CD013773.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"498.e1","DOI":"10.1016\/j.clgc.2022.06.006","article-title":"Primary tumor shrinkage and the effect on metastatic disease and outcomes in patients with advanced kidney cancer with intermediate or poor prognosis treated with nivolumab plus ipilimumab or cabozantinib","volume":"20","author":"Iacovelli","year":"2022","journal-title":"Clinical Genitourinary Cancer"},{"issue":"6","key":"10.1002\/14651858.CD013773.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00002371-199711000-00008","article-title":"Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma","volume":"20","author":"Kudoh","year":"1997","journal-title":"Journal of Immunotherapy"},{"issue":"4","key":"10.1002\/14651858.CD013773.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euo.2019.04.007","article-title":"Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates?","volume":"2","author":"Larcher","year":"2019","journal-title":"European Urology Oncology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0124|cit124","unstructured":"Ljungberg B Albiges L Bedke J Bex A Capitanio U Giles RH EAU Guidelines on Renal Cell Carcinoma. European Association of Urology, 2022 Available from uroweb.org\/guidelines\/renal-cell-carcinoma"},{"issue":"6","key":"10.1002\/14651858.CD013773.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s11523-018-0601-2","article-title":"Should CARMENA really change our attitude towards cytoreductive nephrectomy in metastatic renal cell carcinoma? A systematic review and meta-analysis evaluating cytoreductive nephrectomy in the era of targeted therapy","volume":"13","author":"Massari","year":"2018","journal-title":"Targeted Oncology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"103293","DOI":"10.1016\/j.critrevonc.2021.103293","article-title":"Cytoreductive nephrectomy in the era of targeted\u2013 and immuno\u2013 therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature","volume":"160","author":"Mazzaschi","year":"2021","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"10","key":"10.1002\/14651858.CD013773.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD013773.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0130|cit130","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"issue":"24","key":"10.1002\/14651858.CD013773.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013773.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.clgc.2016.04.001","article-title":"Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis","volume":"14","author":"Petrelli","year":"2016","journal-title":"Clinical Genitourinary Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/KCA-170009","article-title":"Systematic review: perioperative systemic therapy for metastatic renal cell carcinoma","volume":"1","author":"Pili\u00e9","year":"2017","journal-title":"Kidney Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/jkcvhl.2019.114","article-title":"Is cytoreductive nephrectomy still a standard of care in metastatic renal cell carcinoma?","volume":"6","author":"Renner","year":"2019","journal-title":"Journal of Kidney Cancer and VHL"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0135|cit135","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2023"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jrsm.1078","article-title":"Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions","volume":"4","author":"Sch\u00fcnemann","year":"2013","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0137|cit137","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0138|cit138","unstructured":"SEER Cancer Stat Facts: Kidney and Renal Pelvis Cancer seer.cancer.gov\/statfacts\/html\/kidrp.html"},{"issue":"1","key":"10.1002\/14651858.CD013773.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-5347(17)35986-4","article-title":"Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma","volume":"149","author":"Sella","year":"1993","journal-title":"Journal of Urology"},{"issue":"7","key":"10.1002\/14651858.CD013773.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fonc.2017.00107","article-title":"Surgical management of advanced and metastatic renal cell carcinoma: a multidisciplinary approach","volume":"31","author":"Shinder","year":"2017","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jclinepi.2019.10.015","article-title":"GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles","volume":"118","author":"Skoetz","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"23","key":"10.1002\/14651858.CD013773.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"00217","DOI":"10.1016\/j.euo.2023.10.002","article-title":"Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"S2588-9311","author":"Takemura","year":"2023","journal-title":"European Urology Oncology"},{"key":"10.1002\/14651858.CD013773.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"22","key":"10.1002\/14651858.CD013773.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013773.pub2-BIB0146|cit146","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013773","article-title":"Cytoreductive nephrectomy in metastatic renal cell carcinoma","author":"Bellut","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:47:21Z","timestamp":1745326041000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013773.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":146,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013773.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]}}}